Milestones :: Perspectives :: Research
World leaders make historic commitments to provide equal access to vaccines for all
:: The Global Vaccine Summit, hosted by the UK, raises US$ 8.8 billion from 32 donor governments and 12 foundations, corporations and organisations to immunise 300 million children and support the global fight against COVID-19
:: US$ 567 million also raised for new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries
:: Boris Johnson: “Together we rise to fulfil the greatest shared endeavour of our lifetime – the triumph of humanity over disease, now and for the generations that follow.”
London, 4 June 2020 – World leaders have pledged an additional US$ 8.8 billion for Gavi, the Vaccine Alliance, far exceeding the target of US$ 7.4 billion.
The funding will help immunise 300 million more children in the world’s poorest countries against diseases like measles, polio and diphtheria by the end of 2025. It will also support health systems to withstand the impact of coronavirus and maintain the infrastructure necessary to roll out a future COVID-19 vaccine on a global scale.
The pledges were made at the Global Vaccine Summit 2020, hosted by UK Prime Minister Boris Johnson. Representatives from 52 countries, including 35 Heads of State, joined leaders from global health organisations, the private sector, vaccine manufacturers and civil society organisations to support the Vaccine Alliance’s work protecting almost half the world’s children against deadly, preventable infectious diseases..
The UK remains the Vaccine Alliance’s largest donor, pledging the equivalent of £330 million per year over the next five years. Other top donors include the Bill & Melinda Gates Foundation, Norway, Germany and the United States. Eight countries made their first ever pledge to Gavi, including Bhutan, Burkina Faso, Cameroon, Finland, Greece, New Zealand, Portugal and Uganda…
…Over the next five years, we will also see the largest investment in immunisation ever made by lower-income countries.
Gavi-supported countries will contribute US$ 3.6 billion towards the cost of buying vaccines – more than double the amount for the 2016-2020 period and more than 40% of the total estimated cost of supplying vaccines to these countries. They are also expected to invest around US$ 6 billion in immunisation service delivery costs over the same period. The dire economic effects of the COVID-19 pandemic may, however, disrupt these estimates.
Gavi’s market-shaping efforts to make life-saving vaccines more affordable have seen a 21% price reduction for fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines – from $20.01 in 2015 to $15.90 in 2018…
…The world’s biggest vaccine manufacturers also committed to continue supplying the billions of doses needed to continue increasing vaccine coverage across Africa and Asia. The Vaccine Alliance is one of the world’s largest and most successful public-private partnerships, and the wider private sector continued to show support for its mission with the announcement of more than US$ 70 million of new pledges and partnerships, bringing new technology, networks and expertise to help solve some of global health’s most intractable problems.
“On behalf of the countless vaccinators, supply chain workers, programme managers and the many, many others that work tirelessly every day to ensure children in vulnerable countries continue to receive lifesaving vaccines – thank you,” said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. “We have made incredible progress over the past two decades improving vaccine coverage and reducing child mortality across Africa and Asia. This funding will give countries new hope that, despite the devastating impact of COVID-19, this progress can be sustained and built on. The Alliance will now get to work making this happen.”
The Global Vaccine Summit also saw the launch of the Advance Market Commitment for COVID-19 Vaccines (Covax AMC), a new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries. This is the first building block towards a global mechanism to ensure equitable access to future COVID-19 vaccines. US$ 567 million was raised today in initial seed money for the AMC from 12 donors…
Bill & Melinda Gates Foundation pledges $1.6 billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines
JUNE 04, 2020
Global leaders unite to safeguard 300 million more children from disease and mitigate consequences of COVID-19
Gavi launches innovative financing mechanism for access to COVID-19 vaccines
:: Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders
:: New financing mechanism, aimed at supporting affordable access for developing countries, is first building block in broader initiative to create a Covax Facility for global access to eventual COVID-19 vaccines
:: Ngozi Okonjo-Iweala: “The Gavi Covax AMC increases the likelihood that when we have a successful vaccine or vaccines, it will be available in sufficient quantities and affordable to developing countries.”
Geneva, 04 June 2020 – Gavi, the Vaccine Alliance today launched the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), a new financing instrument aimed at incentivising vaccine manufacturers to produce sufficient quantities of eventual COVID-19 vaccines, and to ensure access for developing countries.
The Gavi Covax AMC is being launched with an initial goal of raising US$ 2 billion; enough for Gavi-supported countries to immunise health care workers as well as high-risk individuals, and create a flexible buffer of doses to be deployed where needed most.
It will not be a stand-alone financing instrument but rather represents the first building block in broader efforts to develop a COVID-19 Global Vaccine Access Facility (Covax Facility) aimed at ensuring equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.
The Gavi Covax AMC is inspired by similar mechanisms that have successfully secured equitable global access to pneumococcal and Ebola vaccines. By providing volume guarantees for specific candidates before they are licenced, as well as market-wide guarantees, the Gavi Covax AMC will encourage manufacturers to make investments in production capacity. This in turn increases supply availability and reduces the amount of time it takes for licenced vaccines to become available, particularly to the poorest countries around the world.
“Today’s launch moves us one step closer to the essential vision of equitable access for all,” said Dr Ngozi Okonjo-Iweala, Chair of the Gavi Board. “By de-risking the cost of investing in high volumes of manufacturing against an unknown outcome – and making sure those investments are made now – the Gavi Covax AMC increases the likelihood that when we have a successful vaccine or vaccines, it will be available in sufficient quantities and affordable to developing countries…
HPV vaccine manufacturers commit to provide enough supply to immunize at least 84 million girls in Gavi countries
:: On the eve of the Global Vaccine Summit 2020, five manufacturers commit to increasing and prioritising HPV vaccine supply to Gavi-supported countries, which have among the highest cervical cancer burdens in the world
:: Gavi estimates that up to 84 million girls in the poorest countries could receive HPV vaccines in the next 5-year period, averting 1.4 million future cervical cancer deaths
:: Dr Seth Berkley: “We are extremely grateful to MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. and Walvax for these commitments, which should have a profound impact on women’s lives”
Geneva, 03 June 2020 – Vaccine manufacturers MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. (SII) and Walvax have pledged to ramp up human papillomavirus (HPV) vaccine supply availability for Gavi-supported countries, ahead of tomorrow’s Global Vaccine Summit 2020.
This commitment is part of an ongoing UNICEF-led tender that aims to enable Gavi to dramatically increase its reach from 50 million girls, as initially planned, to 84 million girls during the next five-year period, leading to the prevention of an estimated 1.4 million future deaths from cervical cancer…
WHO welcomes crucial new funding for vaccines
4 June 2020 News release
WHO welcomes funding commitments made at today’s Global Vaccine Summit, hosted virtually by the UK government. The Summit is Gavi, the Vaccine Alliance’s third pledging conference and follows the successful Berlin summit in January 2015.
The new pledges will enable Gavi to protect the next generation and reduce disease inequality by reaching an additional 300 million children with vaccines by 2025.
“Thanks to vaccines, hundreds of millions of deaths have been prevented. Polio has been pushed to the brink of eradication, and just in the past few years new vaccines have become available for Ebola and malaria,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
“But vaccines only realize their true power when they are deployed to protect the poorest and most vulnerable. The COVID-19 pandemic is unravelling many of the gains we have made, with vaccination campaigns for polio, cholera, measles, diphtheria, and meningitis.”
The bold funding commitments mean that the Gavi Alliance will be better able to maintain immunization in lower-income countries, mitigating the impact of the COVID-19 pandemic. They will also help strengthen health systems.
The backdrop of the COVID-19 pandemic is a sobering reminder of how much individual health depends on collective health and the critical role that vaccines play in keeping the global population safe and healthy. The Summit also highlighted how important a safe, effective and equitably accessible vaccine will be in controlling COVID-19.
The Global Vaccine Summit marks 20 years since Gavi was founded. Dr Tedros added: “We join Gavi in celebrating the collective success of this great Alliance. These pledges are not just an investment in the Alliance of which we are a very proud partner; they are an advance on our shared vision of a healthier, safer and fairer world.”